Phase 1-2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia

被引：6

作者：

Kearns, Pamela ^{[1
]}

Zwaan, Christian M. ^{[2
]}

Reinhardt, Dirk ^{[3
]}

Gibson, Brenda ^{[4
]}

Moreno, Lucas ^{[5
]}

Nysom, Karsten ^{[6
]}

Nakahara, Susumu ^{[7
]}

Huang, Fei ^{[8
]}

Zhou, Wangda ^{[8
]}

Parasrampuria, Dolly A. ^{[8
]}

Nemat, Sepideh ^{[9
]}

机构：

[1] Univ Birmingham, NIHR Birmingham Biomed Res Ctr, Birmingham, W Midlands, England

[2] Erasmus MC, Sophia Childrens Hosp, Rotterdam, Netherlands

[3] Univ Hosp Essen, Essen, Germany

[4] Royal Hosp Children, Glasgow, Lanark, Scotland

[5] Hosp Nino Jesus, Madrid, Spain

[6] Rigshosp, Copenhagen, Denmark

[7] Janssen R&D, Tokyo, Japan

[8] Janssen R&D, Spring House, PA USA

[9] Janssen R&D, High Wycombe, Bucks, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 186卷 / 03期

关键词：

decitabine; cytarabine; acute myeloid leukaemia; DNA methylation; ESR1; CDKN2B; VALPROIC ACID; METHYLATION; COMBINATION;

D O I：

10.1111/bjh.15847

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E7 / E11

页数：5

共 9 条

[1] Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients [J].

Achille, Nicholas J. ;

Othus, Megan ;

Phelan, Kathleen ;

Zhang, Shubin ;

Cooper, Kathrine ;

Godwin, John E. ;

Appelbaum, Frederick R. ;

Radich, Jerald P. ;

Erba, Harry P. ;

Nand, Sucha ;

Zeleznik-Le, Nancy J. .

LEUKEMIA RESEARCH, 2016, 42 :68-74

[2] Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia [J].

Blum, William ;

Klisovic, Rebecca B. ;

Hackanson, Bjoern ;

Liu, Zhongfa ;

Liu, Shujun ;

Devine, Hollie ;

Vukosavljevic, Tamara ;

Huynh, Lenguyen ;

Lozanski, Gerard ;

Kefauver, Cheryl ;

Plass, Christoph ;

Devine, Steven M. ;

Heerema, Nyla A. ;

Murgo, Anthony ;

Chan, Kenneth K. ;

Grever, Michael R. ;

Byrd, John C. ;

Marcucci, Guido .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) :3884-3891

[3] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].

Cheson, BD ;

Bennett, JM ;

Kopecky, KJ ;

Büchner, T ;

Willman, CL ;

Estey, EH ;

Schiffer, CA ;

Döhner, H ;

Tallman, MS ;

Lister, TA ;

LoCocco, F ;

Willemze, R ;

Biondi, A ;

Hiddemann, W ;

Larson, RA ;

Löwenberg, B ;

Sanz, MA ;

Head, DR ;

Ohno, R ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649

[4] Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia [J].

Garcia-Manero, Guillermo ;

Kantarjian, Hagop M. ;

Sanchez-Gonzalez, Blanca ;

Yang, Hui ;

Rosner, Gary ;

Verstovsek, Srdan ;

Rytting, Michael ;

Wierda, William G. ;

Ravandi, Farhad ;

Koller, Charles ;

Xiao, Lianchun ;

Faderl, Stefan ;

Estrov, Zeev ;

Cortes, Jorge ;

O'Brien, Susan ;

Estey, Elihu ;

Bueso-Ramos, Carlos ;

Fiorentino, Jackie ;

Jabbour, Elias ;

Issa, Jean-Pierre .

BLOOD, 2006, 108 (10) :3271-3279

[5] A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML [J].

Gore, Lia ;

Triche, Timothy J., Jr. ;

Farrar, Jason E. ;

Wai, Daniel ;

Legendre, Christophe ;

Gooden, Gerald C. ;

Liang, Winnie S. ;

Carpten, John ;

Lee, David ;

Alvaro, Frank ;

Macy, Margaret E. ;

Arndt, Carola ;

Barnette, Philip ;

Cooper, Todd ;

Martin, Laura ;

Narendran, Aru ;

Pollard, Jessica ;

Meshinchi, Soheil ;

Boklan, Jessica ;

Arceci, Robert J. ;

Salhia, Bodour .

CLINICAL EPIGENETICS, 2017, 9

[6] Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia [J].

Hess, Corine J. ;

Errami, Abdellatif ;

Berkhof, Johannes ;

Denkers, Fedor ;

Ossenkoppele, Gert J. ;

Nygren, Anders O. H. ;

Schuurhuis, Gerrit J. ;

Waisfisz, Quinten .

LEUKEMIA & LYMPHOMA, 2008, 49 (06) :1132-1141

[7] Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia [J].

Kantarjian, Hagop M. ;

Thomas, Xavier G. ;

Dmoszynska, Anna ;

Wierzbowska, Agnieszka ;

Mazur, Grzegorz ;

Mayer, Jiri ;

Gau, Jyh-Pyng ;

Chou, Wen-Chien ;

Buckstein, Rena ;

Cermak, Jaroslav ;

Kuo, Ching-Yuan ;

Oriol, Albert ;

Ravandi, Farhad ;

Faderl, Stefan ;

Delaunay, Jacques ;

Lysak, Daniel ;

Minden, Mark ;

Arthur, Christopher .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2670-2677

[8] Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia [J].

Leonard, Sarah M. ;

Perry, Tracey ;

Woodman, Ciaran B. ;

Kearns, Pamela .

PLOS ONE, 2014, 9 (01)

[9] Population Pharmacokinetic Analysis of Decitabine in Pediatric Patients With Acute Myeloid Leukemia [J].

Zhou, Wangda ;

Parasrampuria, Dolly A. ;

Nemat, Sepideh ;

Nakahara, Susumu ;

Poggesi, Italo ;

Massarella, Joseph ;

Zhang, Liping ;

Appiani, Carlos .

JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (05) :668-676

← 1 →